Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Link to XBRL Interactive Data 30 June 2018

September 3, 2018 Kerry Rowe

https://www.sec.gov/cgi-bin/viewer?action=view&cik=1131343&accession_number=0001144204-18-047425&xbrl_type=v

Post navigation

PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

Related Posts

Prana Completes Recruitment in Huntington Trial

July 17, 2013

Life Biosciences LLC leads strategic investment of up to A$44.5 million in Prana

December 27, 2018

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

October 5, 2018

Recent Posts

Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference
Alterity to present at the 7th International Congress of Multiple System Atrophy
Alterity Half Year Results and Investor Webcast Notification
Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065